Buccal cytology stayed normal in treated Sudanese children with sickle cell anaemia
In a pilot case-control study from Sudan, sickle cell anaemia did not produce visible cytomorphological abnormalities in buccal mucosal epithelial cells among children receiving treatment. The comparison was straightforward and clinically sober: 40 children with homozygous HbSS disease were matched against 40 clinically healthy children of similar age and sex, and neither group showed the predefined nuclear or cytoplasmic changes on exfoliative cytology.
The result is modest in scope, but it is still clinically useful. Oral epithelial cells are exposed to chronic hypoxia, inflammation, and microvascular compromise in sickle cell disease, so a detectable smear-level difference might have offered a simple window into systemic injury. Instead, the slides remained morphologically unremarkable under the conditions tested, suggesting that any oral epithelial effect was either absent, below the detection threshold of this technique, or altered by treatment status and the narrow study design.
What the smear method actually looked for
Buccal smears were collected from the inner cheek of each participant, fixed immediately in 95% ethanol, stained with the Papanicolaou technique, and examined by a cytopathologist blinded to group allocation. Each slide was screened across its full extent for nuclear enlargement, hyperchromasia, irregular nuclear membrane contours, and cytoplasmic change. Those are not trivial descriptors; they are the kinds of features cytologists use when tissue is reacting to stress, injury, or dysplastic transformation.
No such abnormalities were identified in either cohort.
The absence of abnormalities matters because the oral mucosa is a rapidly renewing epithelium with biologic vulnerability to systemic disease. In sickle cell anaemia, recurrent vaso-occlusion and hemolysis can alter oxygen delivery and tissue homeostasis. If those processes were leaving a measurable imprint on the buccal lining in this treated pediatric group, the smear strategy used here did not capture it. The finding does not rule out microscopic injury at a molecular level, and it does not address whether untreated disease would look different. It does, however, place a practical boundary around what conventional exfoliative cytology can reveal in this setting.
The cohort was small, young, and clinically treated
The case group included 40 Sudanese children with HbSS who were already receiving treatment. Of these, 22 were female and 18 were male, and the mean age was 9.48 years, with ages ranging from 3 to 15 years. The control group consisted of 40 clinically healthy children matched for age and sex. The study used descriptive analysis in SPSS version 26.0, which is appropriate for a pilot effort but leaves the work without the statistical depth needed to detect subtle group effects.
This narrow design shapes how the result should be read. A treated cohort can look very different from an untreated one, especially in a disorder where disease burden fluctuates with crisis frequency, baseline hemoglobin physiology, transfusion history, hydroxyurea exposure, and overall access to care. None of those variables were positioned here as analytic comparators. As a result, the clean cytology result should be interpreted as an observation in a managed pediatric sample, not as a broad statement about sickle cell anaemia itself.
A negative oral finding does not equal biologic silence
Sickle cell disease remains a systemic illness with consequences that can extend to the mouth, jaw, bone, and mucosa. The pathophysiology is built on deformed red cells, impaired microcirculatory flow, and intermittent tissue ischemia. In theory, a chronically stressed oral epithelium could show nuclear enlargement or membrane irregularity if cell turnover or repair were altered by repeated hypoxic injury. But biology does not always translate into visible cytology, especially when the disease is being treated and the cohort is small.
A one-sentence clinical reality sits at the center of this study: the buccal smear did not distinguish treated children with HbSS from healthy peers.
That should not be mistaken for proof that the oral mucosa is unaffected. It is better understood as evidence that this particular morphologic assay, in this specific pediatric sample, did not expose a measurable difference. For clinicians, the implication is restrained but important: routine buccal cytology cannot yet be treated as a surrogate marker of disease burden or treatment response in pediatric sickle cell anaemia.
Why the finding is limited, and why that still matters
The investigators themselves faced a major interpretive constraint: there was no pretreatment assessment and no untreated sickle cell group. Without those comparators, the study cannot separate treatment effect from baseline disease biology. A normal smear in a treated child could mean the therapy helped preserve epithelial integrity, but it could just as easily mean the mucosa was never morphologically abnormal enough to be detected by Pap staining in the first place.
The other limitation is structural. This was a pilot case-control study with a total sample of 80 children, and the analysis was descriptive. Pilot studies are valuable when they test feasibility, sampling, and laboratory workflow, but they rarely settle mechanism. Here, the laboratory process was tidy and the blinded cytopathology review strengthens internal consistency, yet the study still lacks the scale and comparator structure needed for causal interpretation.
The practical consequence is simple. Oral exfoliative cytology may remain useful in broader screening contexts, but it is not ready to serve as a biomarker of sickle cell-related mucosal injury in treated children based on this dataset.
What larger studies would need to answer next
Future work would need to move beyond a single treated cohort and a healthy control arm. A stronger design would compare untreated children, treated children, and possibly longitudinal samples before and after therapy initiation. It would also need a larger sample size and outcome measures that extend beyond morphology alone, because early tissue stress may show up biochemically or ultrastructurally before it becomes visible under routine light microscopy.
The study was approved by the ethics committee of the Faculty of Medical Laboratory Sciences at the University of Khartoum, and informed consent was obtained from parents. The work received no funding, which often limits scale but also makes the negative result easier to view as an unembellished pilot observation rather than a sponsor-driven claim.
For now, the data answer a narrower question than the topic headline first suggests. In Sudanese children with sickle cell anaemia who were already receiving treatment, buccal mucosal epithelial cells did not show the morphologic abnormalities sought by Pap-based exfoliative cytology. The next question is not whether the mouth can be affected by sickle cell disease—it can—but whether a different design, a different biomarker, or an untreated comparator can reveal what this pilot study could not.